Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does the kinin system mediate in cardiovascular abnormalities? An overview.

Jagdish N Sharma1

  • 1Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.

Journal of Clinical Pharmacology
|October 11, 2003
PubMed
Summary

The kallikrein-kinin system plays a vital role in heart health. Its deficiency contributes to cardiovascular diseases, but kallikrein gene therapy shows promise for treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chediak-Higashi Syndrome With Epstein-Barr Virus Triggered Hemophagocytic Lymphohistiocytosis: A Case Report.

Cureus·2020
Same author

Basic and clinical aspects of bradykinin receptor antagonists.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2014
Same author

The kallikrein-kinin pathways in hypertension and diabetes.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2014
Same author

The kinin system in hypertensive pathophysiology.

Inflammopharmacology·2012
Same author

Hypertension and the bradykinin system.

Current hypertension reports·2009
Same author

Cardiovascular activities of the bradykinin system.

TheScientificWorldJournal·2008

Area of Science:

  • Cardiovascular Physiology
  • Molecular Medicine
  • Pharmacology

Background:

  • The kallikrein-kinin system (KKS) is present in cardiac muscle, and its components are crucial for normal cardiac function.
  • Evidence suggests KKS deficiency contributes to cardiovascular diseases like hypertension, ischemia, and myocardial infarction.
  • Reduced KKS activity is implicated in conditions such as diabetes, cardiac failure, and left ventricular hypertrophy.

Purpose of the Study:

  • To investigate the role of the kallikrein-kinin system in cardiovascular health and disease.
  • To explore the therapeutic potential of modulating the KKS for cardiovascular and renal disorders.

Main Methods:

  • Review of clinical and experimental data linking KKS activity to cardiovascular pathologies.
  • Analysis of the mechanisms underlying the cardioprotective effects of angiotensin-converting enzyme inhibitors.

Related Experiment Videos

  • Evaluation of kallikrein gene delivery and kinin agonists as therapeutic strategies.

    • Main Results:

    • The KKS is integral to cardiac function, and its deficiency is linked to various cardiovascular diseases.
    • Angiotensin-converting enzyme inhibitors exert cardioprotective effects partly through kinin release, aiding in left ventricular hypertrophy regression.
    • Kallikrein gene delivery demonstrates broad beneficial effects, suggesting its potential in treating hypertension and cardiovascular/renal diseases.

    Conclusions:

    • The kallikrein-kinin system is a critical factor in maintaining cardiovascular homeostasis.
    • Modulating the KKS, via gene therapy or agonists, offers promising therapeutic avenues for cardiovascular and renal diseases.
    • Future development of stable kinin agonists could provide new treatment options for these conditions.